Comparative Pharmacology
Head-to-head clinical analysis: ENSTILAR versus RAYALDEE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSTILAR versus RAYALDEE.
ENSTILAR vs RAYALDEE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSTILAR is a combination of calcipotriene (a vitamin D analog) and betamethasone dipropionate (a corticosteroid). Calcipotriene binds to vitamin D receptors, modulating cell proliferation and differentiation. Betamethasone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Rayaldee (calcifediol) is a vitamin D3 analog that is converted to the active hormone calcitriol by 1-alpha-hydroxylase in the kidney. It acts as a vitamin D receptor agonist, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and suppressing parathyroid hormone (PTH) secretion. In CKD patients, it lowers elevated PTH levels.
Apply to affected area once daily for up to 4 weeks. Maximum 100 g/day or 30 g/week. Not for use on face, axillae, or groin.
30 mcg orally once daily at bedtime.
None Documented
None Documented
Calcipotriol: terminal half-life ~12 hours. Betamethasone dipropionate: terminal half-life ~16-22 hours. Clinically, this supports once-daily application.
Terminal elimination half-life is approximately 14-19 hours, reflecting the extended-release formulation designed for once-daily dosing.
Calcipotriol is primarily excreted via bile/feces (approximately 70% of absorbed dose). Betamethasone dipropionate is mainly excreted renally (60-70% as metabolites) and up to 20-30% via feces. For the combination, renal excretion of betamethasone metabolites predominates, with fecal excretion of calcipotriol.
Primarily fecal via biliary excretion (70-80%); renal excretion accounts for <10% of total clearance.
Category C
Category C
Topical Corticosteroid and Vitamin D Analog
Vitamin D Analog